WaveMan · Form 4
Wyzga Michael S insider trades
> Search tickers & screens ⌘K
LIVE

Wyzga Michael S insider trades

Wyzga Michael S has filed 18 Form 4s with the SEC that we hold, for X4 Pharmaceuticals, Inc (XFOR) (Director), Mereo BioPharma Group plc (MREO) (Director), Invivyd, Inc. (IVVD) (Director) and Tvardi Therapeutics, Inc. (TVRD) (Director), among 5 companies in all. Across all of them we count 1 purchase worth $30.0K and 0 sales worth $0 reported on Form 4. None of these purchases or sales is dated in the last 12 months. The largest single trade was a purchase of 25,000 shares of X4 Pharmaceuticals, Inc worth $30.0K, dated 2023-08-18. The first filing on our record is dated 2021-08-09 and the latest 2026-06-11.

X4 Pharmaceuticals, Inc (XFOR)

Director · 6 filings · 1 purchase or sale
Trade dateCodeSharesValue as filedFiled
2023-08-18P, purchase reported on Form 425,000$30.0K2023-08-22

Mereo BioPharma Group plc (MREO)

Director · 4 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Invivyd, Inc. (IVVD)

Director · 3 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Tvardi Therapeutics, Inc. (TVRD)

Director · 3 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

LOGC (LOGC)

Director · 2 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1201256) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms